The fight against the coronavirus pandemic continues throughout the world. Since the final months of 2020, the different Pharmaceutical companies around the world have developed multiple vaccines against COVID that have been approved by the different regulatory agencies.
The next one in the European Union could be Johnson & Johnson.
In the last hours, to the list of approved vaccines, the one developed by the CanSino company (China) has been added. The biotech company filed a petition for approval of its vacuna AD5-nCoV after presenting some results in phase III with an efficiency of up to 90%.
In a statement, the Asian company confirms that the results of its international trial had a 65.28% efficacy to prevent symptomatic cases and 90.07% for severe symptoms at 28 days to inoculate the first and only dose.
It is a vaccine that is based on recombinant SARS-CoV-2 proteins in an adenovirus and it is the first approved with these characteristics in China.
Fighting other diseases
Founded and directed by Yu Xuefeng, the company is currently working on the development of up to 16 vaccines. However, not all with against the SARS-CoV-2 coronavirus: in total, 13 infectious diseases such as meningitis, Ebola, tuberculosis, or pneumonia. The already approved vaccine was the first to have a patent.
However, in addition to making progress in the trials of their vaccines, they are also focusing on building a cold chain logistics system and an information system together with the local Army.
As they have assured, this vaccine will be distributed specifically in the countries with the greatest difficulty to develop the logistics required for vaccine distribution.
Massive production
For this year, the Asian giant hopes to increase its production of COVID vaccines up to 2 billion doses, while by 2022 it hopes to double this figure, thus becoming the large drug distributor in developing countries.
According to the president of the China Vaccine Industry Association, Feng Duojia, the 4,000 million doses by 2022 would cover about 40% of global demand. In Latin America, a dozen countries have already received the first doses of vaccines developed in China.